Abstracts tagged "pain"

Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 1124 • ACR Convergence 2021
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Lucy Abraham¹, Robert Dworkin², Dennis C. Turk³, John D. Markman², David A. Williams⁴, Andrew G Bushmakin⁵, Jerry A. Hall⁶, David C. Semel⁷, Joseph C Cappelleri⁵ and Ruoyong Yang⁸, ¹Pfizer Ltd., Tadworth, United Kingdom, ²University of Rochester, Rochester, NY, ³University of Washington, Seattle, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, New York, NY, ⁸Pfizer Inc., New York, NY
Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
Abstract Number: 1614 • ACR Convergence 2021
Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain
Sabrina Gmuca¹, Pamela Weiss¹, Mackenzie McGill¹, Maitry Sonagra², David D. Sherry¹, Peter Cronholm³, Jeffrey S. Gerber¹, Tonya M. Palermo⁴, Jami F. Young¹ and Abby R. Rosenberg⁴, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Cherry Hill, NJ, ³University of Pennsylvania, Philadelphia, PA, ⁴Seattle Children's Hospital, Seattle, WA
Background/Purpose: Chronic musculoskeletal pain (CMP) affects up to 40% of youth and is associated with physical disability and psychological distress. Resilience coaching interventions, such as…
Abstract Number: 0118 • ACR Convergence 2021
Multidimensional Phenotypes of Sleep Quality Using the Pittsburg Quality Sleep Index and Associations Among Sleep Dimensions and Symptoms in Women Diagnosed with Fibromyalgia
Victoria Menzies, Debra Lynch Kelly and Miichael Weaver, University of Florida, Gainesville, FL
Background/Purpose: There are over 10 million people in the United States suffering with fibromyalgia syndrome (FMS). Individuals with FMS typically report multiple concurrent symptoms including…
Abstract Number: 0723 • ACR Convergence 2021
Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Persons who seek treatment for osteoarthritis (OA) are likely doing so when experiencing a flare-up in pain. Due to natural fluctuation of pain, this…
Abstract Number: 1166 • ACR Convergence 2021
Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe
Rebecca Fitzpatrick¹, Najia Shakoor², Michael Grant² and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: With the legalization of marijuana in many states, rheumatologists are having increased inquiries from patients regarding marijuana use in addition to their pain regimen.…
Abstract Number: 1617 • ACR Convergence 2021
Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
Maitry Sonagra¹, Jeremy Jones², Mackenzie McGill³ and Sabrina Gmuca³, ¹Seattle Children's Hospital, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Adverse childhood experiences (ACEs) serve as stressors that can have negative, lasting effects on health and wellbeing. While there has been increasing evidence to…
Abstract Number: 0121 • ACR Convergence 2021
The Efficacy of Group Behavioral Activation versus Usual Treatment in Patients with Fibromyalgia and Major Depression
Josefina Duran, Alvaro Verges, Ana Rocío Vázquez-Taboada, Matias Gonzalez and Lydia Gomez-Pérez, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Fibromyalgia (FM) and major depression frequently coexist. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce.…
Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Martin Boucher¹, Kenneth Verburg², Puneet Gaitonde² and Scott marshall¹, ¹Pfizer R&D Ltd., Sandwich, United Kingdom, ²Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…
Abstract Number: 1200 • ACR Convergence 2021
Predicting Progression to RA in Patients with Seropositive Arthralgia
Aine Gorman¹, Keelin Flynn², Matthew Turk¹, Candice Low³, Kieran Murray⁴, Carl Orr⁵, Phil Gallagher⁵, Lorna Freeman², Edel Meaney², Eamonn Molloy⁶, Lorraine O Neill⁷, Ursula Fearon⁸ and Douglas Veale⁹, ¹St Vincents Hospital, Dublin, Ireland, ²The Centre for Arthritis and Rheumatic Disease, EULAR Centre of Excellence, St. Vincent’s University Hospital and University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶St Vincent's Healthcare Group, Dublin, Ireland, ⁷St. Vincent's Hospital, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory condition often associated with joint destruction, disability, and reduced life expectancy. Before RA diagnosis, some patients may…
Abstract Number: 1674 • ACR Convergence 2021
Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Boulos Haraoui¹, Majed Khraishi², Denis Choquette¹, Larissa Lisnevskaia³, Michelle Teo⁴, Cassandra Kinch⁵, Corina Galos⁶, Patrice Roy⁵, David Gruben⁷, John C Woolcott⁸, Julie Vaillancourt⁹, John Sampalis¹⁰ and Edward Keystone¹¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada, ³Oshawa Clinic, Oshawa, ON, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Canada ULC, Kirkland, SK, Canada, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA, ⁹JSS Medical Research, Montréal, QC, Canada, ¹⁰McGill University and JSS Medical Research, Montréal, QC, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor (JAKi) for the treatment of RA. CANTORAL is the first large-scale, national, observational study assessing effectiveness and…
Abstract Number: 0123 • ACR Convergence 2021
Vestibulocortical Stimulation with Caloric Irrigation Reduces Pain and Improves Subjective Well-Being in Fibromyalgia: An Open-Label Pilot Trial
Michael Kaplan¹, Celine Zhou¹, Emily Carroll¹, Alan Weinberg², Daniel Clauw³, Trung Thanh Ngo⁴ and Ioannis Tassiulas⁵, ¹The Mount Sinai Hospital, Manhattan, NY, ²The Mount Sinai Hospital, New York, NY, ³University of Michigan, Ann Arbor, MI, ⁴University of Queensland & Translational Research Institute, Woolloongabba, Australia, ⁵Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Safe and effective therapies for fibromyalgia (FM) remain a major unmet clinical need. Vestibulocortical stimulation (VCS) via caloric irrigation is a safe, inexpensive, non-invasive…
Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Robert Fountaine¹, Robert Dworkin², Anne Hickman¹, Glenn Pixton³, Ed Whalen⁴, Christine West¹ and Kenneth Verburg¹, ¹Pfizer Inc., Groton, CT, ²University of Rochester, Rochester, NY, ³Pfizer Inc., Morrisville, NC, ⁴Pfizer Inc., New York, NY
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
Abstract Number: 1213 • ACR Convergence 2021
Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
Christoph Baerwald¹, Edgar Stemmler², Sixten Gnuechtel², Katharina Birkner², Carsten Holland³, Bjoern Fritz², Daniela Adolf⁴ and Ralf Baron⁵, ¹University Hospital Leipzig, Leipzig, Germany, ²AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ³AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁴StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁵University Hospital Schleswig-Holstein, Kiel, Germany
Background/Purpose: Pain is the symptom with the most significant impact on patients’ lives in rheumatoid arthritis (RA), whereas 17% of German RA patients report severe…
Abstract Number: 1704 • ACR Convergence 2021
Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?
Elena Pogozheva¹, Andrey Karateev¹, Evgeniy Nasonov¹, Alexander Lila¹, Vadim Mazurov², Rusanna Samigullina³, Diana Chakieva⁴, Anna Dadalova⁴, Anna Dyo⁴, Andrey Baranov⁵, Natalia Lapkina⁵, Ekaterina Kol’tsova⁶, Ivan Shchendrigin⁷, Tatyana Rasevich⁸, Antonina Davydova⁹, Irina Shafieva¹⁰, Inna Bashkova¹¹, Daria Bobrikova¹², Irina Kushnir¹³, Elena Kalinina¹⁴, Tatiana Sal’nikova¹⁵, Valentina Sorotskaya¹⁶, Irina Marusenko¹⁷, Olga Semagina¹⁸, Irina Vinogradova¹⁹, Diana Krechikova²⁰, Natalia Kiryukhina²¹, Irina Semizarova²², Dzhamilya Murtazalieva²³ and Marina Semchenkova²⁴, ¹V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ²Mechnikov North-Western State Medical University, Saint Petersburg, Russia, ³Mechnikov North-Western State Medical University, St.Petersburg, Russia, ⁴Mechnikov North-Western State Medical University, St. Petersburg, Russia, ⁵Yaroslavl State Medical University, Yaroslavl, Russia, ⁶Scientific and Research Institute of Health Care Organization, Moscow, Russia, ⁷Stavropol Regional Clinical Hospital, Stavropol, Russia, ⁸Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, ⁹Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, ¹⁰Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, ¹¹Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, ¹²Regional Clinical Hospital No. 1, Tyumen', Russia, ¹³Kemerovo regional clinical hospital, Kemerovo, Russia, ¹⁴Volgograd State Medical University, Volgograd, Russia, ¹⁵Regional Clinical Hospital, Tula, Russia, ¹⁶Tula State Medical University, Tula, Russia, ¹⁷Petrozavodsk State University, Petrozavodsk, Russia, ¹⁸Regional Clinical Hospital, Samara, Russia, ¹⁹Regional Clinical Hospital, Ulyanovsk, Russia, ²⁰Smolensk State Medical University, Smolensk, Russia, ²¹National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, ²²Regional Clinical Hospital, Krasnodar, Russia, ²³Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, ²⁴Medical Clinical Centre, Smolensk, Russia
Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.Methods: The study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].